Left Ventricular Size And Function In Patient With Type 2 Diabetes Mellitus Treated With Dipeptidyl Peptidase-4 Inhibitors

Abstract

Background Patients with type 2 diabetes mellitus (T2DM) present with subclinical left ventricular systolic and/or diastolic dysfunction (LVD). Dipeptidyl peptidase-4 (DPP4) is an integral membrane glycoprotein that modulates the pathological state of diabetes mellitus (DM), and DPP4 inhibitors are a new class of anti-type-2 DM drugs. Recent preclinical studies have associated DPP4 inhibition with improved myocardial systolic and diastolic function, Aim and objectives to assess Effect of DPP4I on LV size and Function in type 2 DM patient, Subjects and methods This study was conducted on 76 patients (46 patients on random anti DM drug other than DPP4i and 30 patients not on DPP4i then they were prescribed by them) in cardiology and internal medicine departments in the faculty of medicine of Mansoura University between 2021-2022, Result There was statistically significant difference between the groups 1&2 and LV diameter IVSD, LV mass, LV mass index. There was statistically significant difference between the groups 1&3 and LV mass index. There was statistically significant difference between the groups 2&3 and LV diameter IVSD, LV mass and LV mass index, Conclusion We demonstrated significant improvements in LV diastolic function in patients treated with a dipeptidyl peptidase-4 inhibitor over 12 months. Therefore, DPP-4 inhibitor seems to have cardioprotective effects independent of glucose control and may have a role in the prevention of diabetic cardiomyopathy,